Appian Medical is leading the way in the innovation of mobile health technologies to solve the universal need for
accessible, accurate, and affordable detection of obstructive sleep apnea.
SnoreSounds utilizes clinically proven algorithms and software to diagnose obstructive sleep apnea (OSA) by analyzing the structural characteristics and sound composition of snoring.
It is the first mobile health app developed to allow easy, definitive detection of OSA in the natural sleep environment, using a smartphone.
SnoreSounds will provide millions of people with an accessible, accurate and affordable method to determine their risk for OSA, without being tethered and trussed with wires, cuffs, straps or head attachments, or having to spend the night in a sleep lab.
The SnoreSounds platform will allow integration with other health and fitness monitoring technologies and health plans, to encourage broad consumer reach and usage.
Pediatric OSA is on the rise in the USA and may be linked with growing prevalence of childhood obesity and diabetes, among other health issues. To make matters worse, the symptoms resulting from sleep-disordered breathing are tied to those of Attention Deficit / Hyperactivity Disorder (ADHD) and may linked to the ADHD epidemic.
Parents and physicians need an easy way to identify children who may be at risk for OSA and who would benefit from appropriate treatment.
Appian Medical is currently developing a second smartphone app that uses highly predictive and clinically validated technique to screen for moderate-to-severe OSA in children.
The Appian Medical team has successfully pioneered innovative devices, diagnostic technologies, and mHealth apps to improve disease
detection, treatment, and monitoring in medical practice.
Michael J. Thomas
Executive Chairman and Managing Director
Chief Marketing Officer
Jonathan Freudman, MD
Michael J. Thomas
Founder, Executive Chairman & Managing Director
Mr. Thomas is the founder and CEO of Appian Medical, a mobile health firm that is developing, validating, and commercializing an algorithm that can diagnose Obstructive Sleep Apnea (OSA) via snore recordings from a smartphone app. Mr. Thomas spent the last 2 ½ years as CEO of iSonea Ltd (ASX:ISN), a publicly traded global, mobile health app developer and medical device manufacturer in the respiratory disease market. He raised $25MM for iSonea and increased the company’s market capitalization from $4MM to $250MM during his tenure. He is a member of the Board of Directors for Circadiance LLC, a specialty CPAP mask manufacturer. He is also the President and CEO of Appian Partners, a medical devices and healthcare services consulting firm. Earlier in his career, Thomas was President and CEO of Sleep Solutions, a VC-‐backed medical device manufacturer. He raised over $50 million in VC funding for that company and launch a new industry in the $5B Sleep Medicine market. He increased the company’s valuation from $1MM to over $70MM and ramped the company’s revenue from $0 to over $20MM during his tenure. Thomas successfully lobbied the largest Managed Care Organizations (MCOs) and the Centers for Medicare and Medicaid Services (CMS) to alter their medical policy and approve reimbursement for in-home sleep apnea diagnostic services. Prior to joining Sleep Solutions, Thomas was EVP of Sales and Marketing for National Sleep Technologies (NST), where he led acquisitions of more than 80 sleep labs, making NST the largest sleep testing company in the US, generating over $20MM in annual revenue. NST was later sold to GE Medical. Earlier in his career, Thomas was Vice President of Sales at Patient InfoSystems (NASDAQ: PATI) and instrumental in taking that company public. He and his team delivered an 80 X return to initial company shareholders at the IPO of PATI. He began his career in sales and marketing at Merck and GlaxoWellcome. Thomas graduated from Cornell University with a degree in Microbiology.
Mr. Michael Cheney has over 30 years of experience as a strategic marketing leader for medical device, pharmaceutical, and biotechnology companies. He has launched major market-shaping brands for Wyeth Laboratories and BASF/Knoll Pharmaceuticals. For six years, he was vice president of marketing and the international business unit at Cyberonics, Inc., a pioneer in neuro-stimulation therapy devices for CNS disorders. He also has extensive experience in the respiratory care & sleep disordered breathing markets; he developed strategies to increase adoption of an innovative home sleep test and business model for the diagnosis of sleep apnea. Most recently, Mr. Cheney was vice president of marketing for iSonea Ltd, a pioneer in mobile health platforms for consumer monitoring and management of asthma.
Dr. Jonathan Freudman has over twenty five years of experience in healthcare encompassing a wide range of clinical, administrative and business challenges. He established Freudman Healthcare Consulting LLC in 2002. His clients include venture capital, medical device and other biotechnology companies. Core competencies include planning and implementation of effective reimbursement strategies. Previously, Dr. Freudman managed Blue Shield of California’s Medical Policy Department. His responsibilities included new technology assessment, medical policy, disease management programs and clinical guideline development. He chaired the health plan’s Pharmacy and Therapeutics committee and served on the national Blue Cross Blue Shield Association (BCBSA) Medical Policy Committee. His career includes 16 years of the practice of general internal medicine at Kaiser Permanente Medical Center in San Rafael, California. Administrative duties at this facility included Department Chief of Internal Medicine as well as the Medical Center’s Chief of Quality. He served on the Board of Directors of the Marin County Medical Society. Dr. Freudman is Board Certified in Internal Medicine with added qualification in Geriatrics. He is a Fellow in the American College of Physicians and is a graduate of the George Washington University School of Medicine He is a faculty member of University of California at San Francisco (UCSF) School of Medicine and a volunteer at the San Rafael RotoCare free clinic for the indigent.